H.C. Wainwright initiated coverage on GRI Bio with a new price target
$GRI
Biotechnology: Pharmaceutical Preparations
Health Care
H.C. Wainwright initiated coverage of GRI Bio with a rating of Buy and set a new price target of $10.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/9/2024 | $10.00 | Buy | H.C. Wainwright |
4 - GRI Bio, Inc. (0001824293) (Issuer)
4 - GRI Bio, Inc. (0001824293) (Issuer)
4 - GRI Bio, Inc. (0001824293) (Issuer)
Company reported $8.2 million in cash and cash equivalents at December 31, 2025 and raised additional $6.5 million in gross proceeds in January 2026 Balance sheet strengthened to fund operations into Q1 2027 Strong Phase 2a clinical data for GRI-0621 in idiopathic pulmonary fibrosis reinforce clinical proof-of-concept and therapeutic differentiation GRI-0803 focused on autoimmune indications with high unmet need advancing through IND-enabling activities LA JOLLA, CA, Feb. 04, 2026 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ:GRI) ("GRI Bio" or the "Company"), a biotechnology company advancing an innovative pipeline of immune cell modulators for the treatment of inflammatory, fibrotic and
Multiple Independent Molecular Signals Converge to Validate GRI-0621 as a Potential Disease-Modifying Therapy LA JOLLA, CA, Jan. 28, 2026 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ:GRI) ("GRI Bio" or the "Company"), a biotechnology company advancing an innovative pipeline of immune cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced additional positive data from its recently completed Phase 2a clinical study of GRI-0621 in Idiopathic Pulmonary Fibrosis ("IPF"), further strengthening potential clinical proof-of-concept and reinforcing the therapeutic differentiation of GRI-0621. Newly reported RNA-sequencing differential gene expression data
Issued Claims Protect Distinct Molecular Designs with Broad Therapeutic Potential Across Inflammatory, Fibrotic, and Autoimmune Diseases LA JOLLA, CA, Jan. 26, 2026 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ:GRI) ("GRI Bio" or the "Company"), a biotechnology company advancing an innovative pipeline of immune cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced that the U.S. Patent and Trademark Office (USPTO) has issued U.S. Patent No. 12,528,775, providing robust new intellectual property protection for novel compound compositions central to the Company's platform of immunomodulators. The newly issued patent includes composition-of-matter c
8-K - GRI Bio, Inc. (0001824293) (Filer)
EFFECT - GRI Bio, Inc. (0001824293) (Filer)
10-K - GRI Bio, Inc. (0001824293) (Filer)
H.C. Wainwright initiated coverage of GRI Bio with a rating of Buy and set a new price target of $10.00
Industry leader Barry Quart, Pharm.D. appointed as Chief Executive Officer succeeding Zheng Wei, Ph.D., who will remain on the Board of Directors and serve as an advisor to assist with the transitionExperienced life science executive David Szekeres appointed as PresidentKleanthis G. Xanthopoulos, Ph.D. appointed as Chair of the Board of Directors SAN DIEGO, CA and TAICANG, China, June 12, 2024 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (NASDAQ:CNTB) (Connect or the Company), a U.S.-headquartered, global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inflammatory diseases through the development of therapies derived from T cel
- Financial executive bringing over 20 years of experience in accounting, finance and management with a foundation established from big four accounting firm LA JOLLA, CA, April 25, 2023 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ:GRI) ("GRI Bio" or the "Company"), a biotechnology company advancing an innovative pipeline of Natural Killer T ("NKT") cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced the appointment of Leanne Kelly as its Chief Financial Officer. Ms. Kelly is an accomplished financial executive with over 20 years of experience leading private and publicly traded companies across life science, technology and e-Commerce